Drugs for Diphtheria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 43)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Aluminium phosphate |
Approved, Investigational |
Phase 4 |
|
7784-30-7 |
|
Synonyms:
ALUMINIUM PHOSPHATE
ALUMINIUM PHOSPHATE GEL
|
ALUMINUM PHOSPHATE
PHOSPHALJEL
|
|
2 |
|
Edetate calcium disodium anhydrous |
Approved, Vet_approved |
Phase 4 |
|
62-33-9, 60-00-4 |
6049 |
Synonyms:
(Ethylenedinitrilo)tetraacetate, ion(4-)
(ethylenedinitrilo)tetraacetic acid, ion(4−)
(Ethylenedinitrilo)tetraacetic acid, ion(4-)
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetate
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetIC ACID
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetic acid
Acid, edetic
Acid, ethylenediaminetetraacetic
Acid, ethylenedinitrilotetraacetic
Acide edetique
Acide ethylenediaminetetracetique
Acido edetico
Acidum edeticum
CaEDTA
Calcioedetato de sodio
Calcitetracemate, disodium
Calcium disodium edetate
Calcium disodium edetic acid
Calcium disodium edta
Calcium disodium ethylenediamine tetraacetate
Calcium disodium ethylenediamine tetraacetic acid
Calcium disodium ethylenediaminetetraacetate
Calcium disodium ethylenediaminetetraacetic acid
Calcium disodium versenate
Calcium disodium versenic acid
Calcium edetate de sodium
CALCIUM EDETATE SODIUM
Calcium edetic acid de sodium
Calcium edta
Calcium sodium 2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate (1/2/1)
Calcium sodium 2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetic acid (1/2/1)
CALCIUM SODIUM EDETATE HYDRATE
Calcium sodium edta
Calcium tetacine
CaNa2Edta
Chelaton 3
Chromium edta
Copper edta
Coprin
Dicobalt edta
Dinitrilotetraacetate, disodium ethylene
Dinitrilotetraacetate, ethylene
Disodium calcitetracemate
Disodium calcium edta
Disodium calcium ethylenediaminetetraacetate
Disodium calcium ethylenediaminetetraacetic acid
Disodium edta
Disodium ethylene dinitrilotetraacetate
Disodium monocalcium edta
Disodium versenate, calcium
Distannous edta
E385
Edathamil
Edetate
Edetate calcium
Edetate calcium disodium
Edetate calcium disodium (anhydrous)
Edetate disodium calcium
Edetate, calcium disodium
Edetates
|
Edetic acid
Edetic acid calcium disodium
Edetic acid calcium disodium (anhydrous)
Edetic acid calcium disodium salt
Edetic acid, calcium salt
Edetic acid, calcium, sodium salt
Edetic acid, chromium salt
Edetic acid, dipotassium salt
Edetic acid, disodium salt
Edetic acid, disodium salt, dihydrate
Edetic acid, disodium, magnesium salt
Edetic acid, disodium, monopotassium salt
Edetic acid, magnesium salt
Edetic acid, monopotassium salt
Edetic acid, monosodium salt
Edetic acid, potassium salt
Edetic acid, sodium salt
EDT
EDTA
EDTA CALCIUM DISODIUM
EDTA calcium disodium salt
EDTA disodium calcium salt
EDTA, calcium derivative, disodium salt
EDTA, chromium
EDTA, copper
EDTA, dicobalt
EDTA, disodium
EDTA, distannous
EDTA, gallium
EDTA, ion(4-)
EDTA, magnesium disodium
EDTA, potassium
EDTA, stannous
EDTHAMIL
Ethylene dinitrilotetraacetate
Ethylene dinitrilotetraacetate, disodium
Ethylenediaminetetraacetate
Ethylenediaminetetraacetate calcium disodium salt
Ethylenediaminetetraacetic acid
Ethylenediaminetetraacetic acid calcium disodium salt
Ethylenedinitrilotetraacetic acid
Gallium edta
H4EDta
Magnesium disodium edta
Monocalcium disodium edta
N,N'-1,2-ethane diylbis-(N-(carboxymethyl)glycine)
N,N'-1,2-ethanediylbis(N-(carboxymethyl)glycine)
Natrii calcii edetas
Potassium edta
Sodium calcium edetate
Sodium calcium edetic acid
SODIUM CALCIUMEDETATE
Stannous edta
Tetacine, calcium
Tetracemate
Versenate
Versenate, calcium disodium
Versene
Versene acid
VERSENE CA
|
|
3 |
|
Iron |
Approved |
Phase 4 |
|
7439-89-6 |
29936 |
Synonyms:
Carbonyl iron
Eisen
Electrolytic iron
Fe
FE (III) ion
Fe(3+)
Fe(III)
fer
Ferric ion
Ferric iron
Ferrum
|
Ferrum metallicum
Hierro
Iron powder
Iron(3+)
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (fe(3+))
Iron, reduced
Reduced iron
|
|
4 |
|
Pentetic acid |
Approved |
Phase 4 |
|
67-43-6 |
|
Synonyms:
[[(Carboxymethyl)imino]bis(1,2-ethanediylnitrilo)tetraacetate]
[[(Carboxymethyl)imino]bis(1,2-ethanediylnitrilo)tetraacetic acid]
1,1,4,7,7-Diethylenetriaminepentaacetate
1,1,4,7,7-Diethylenetriaminepentaacetic acid
Ca-dtpa
CaDTPA
Calcium trisodium pentetate
CaNa-dtpa
Complexon V
DETAPAC
Diethylene triamine pentaacetic acid
Diethylenetriamine pentaacetic acid
Diethylenetriamine-N,N,n',n'',n''-pentaacetate
Diethylenetriamine-N,N,n',n'',n''-pentaacetic acid
Diethylenetriaminepentaacetate
Diethylenetriaminepentaacetic acid
Diethylenetriaminepentacetate
Diethylenetriaminepentacetic acid
DTPA
DTP-A
H5dTpa
Indium dtpa
|
Indium-dtpa
MN-Dtpa
N,N,N',n'',n''-diethylenetriaminepentaacetate
N,N,N',n'',n''-diethylenetriaminepentaacetic acid
N,N-Bis[2-[bis(carboxymethyl)amino]ethyl]glycine
NSC-7340
Pentaacetic acid, diethylenetriamine
Pentacarboxymethyldiethylenetriamine
Pentacin
Pentacine
Pentaind
Pentetate
Pentetate calcium trisodium
Pentetate zinc trisodium
Pentetate, calcium trisodium
Pentetates
PENTETIC ACID
Penthanil
sn-DTPA
Titriplex V
Zinc dtpa
Zinc-dtpa
|
|
5 |
|
Anti-Ulcer Agents |
|
Phase 4 |
|
|
|
6 |
|
Adjuvants, Immunologic |
|
Phase 4 |
|
|
|
7 |
|
Antacids |
|
Phase 4 |
|
|
|
8 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
9 |
|
Antitoxins |
|
Phase 4 |
|
|
|
10 |
|
Fibrinolytic Agents |
|
Phase 4 |
|
|
|
11 |
|
Anticoagulants |
|
Phase 4 |
|
|
|
12 |
|
Iron Chelating Agents |
|
Phase 4 |
|
|
|
13 |
|
Antidotes |
|
Phase 4 |
|
|
|
14 |
|
Protective Agents |
|
Phase 4 |
|
|
|
15 |
|
Chelating Agents |
|
Phase 4 |
|
|
|
16 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
17 |
|
Vaccines |
|
Phase 4 |
|
|
|
18 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
19 |
|
Heptavalent Pneumococcal Conjugate Vaccine |
|
Phase 4 |
|
|
|
20 |
|
Immunoglobulins |
|
Phase 4 |
|
|
|
21 |
|
Antibodies |
|
Phase 4 |
|
|
|
22 |
|
Calcium |
Nutraceutical |
Phase 4 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
23 |
|
Lactitol |
Approved, Investigational |
Phase 3 |
|
585-86-4 |
157355 |
Synonyms:
4-O-beta-D-Galactopyranosyl-D-glucitol
4-O-β-D-Galactopyranosyl-D-glucitol
D-Lactitol
Emportal
Importal
Lactitol
|
Lactitolum
Neda lactiv importal
Oponaf
Pizensy
WURCS=2.0/2,2,1/[H2122H][a2112h-1b_1-5]/1-2/a4-b1
|
|
24 |
|
Deferiprone |
Approved |
Phase 3 |
|
30652-11-0 |
2972 |
Synonyms:
1,2 Dimethyl 3 hydroxy 4 pyridinone
1,2 Dimethyl 3 hydroxypyrid 4 one
1,2 Dimethyl 3 hydroxypyridin 4 one
1,2-Dimethyl-3-hydroxy-4-pyridinone
1,2-Dimethyl-3-hydroxypyrid-4-one
1,2-Dimethyl-3-hydroxypyridin-4-one
3 Hydroxy 1,2 dimethyl 4 pyridinone
3-Hydroxy-1,2-dimethyl-4(1H)-pyridone
3-Hydroxy-1,2-dimethyl-4-pyridinone
APO-066
APO-66
CP20
CP-20
DEFERIPRON
DEFERIPRONA
DEFERIPRONE
DÉFÉRIPRONE
|
DEFERIPRONI
DEFERIPRONUM
DEFERYPRON
DIMETHYLHYDROXYPYRIDONE
DMOHPO
DN-18001AF
DN-180-01-AF
Ferriprox
HDMPP
HDMPP CPD
HDPP
L1
L-1
L1 Oral chelate
PL1
PL-1
|
|
25 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
26 |
|
Cathartics |
|
Phase 3 |
|
|
|
27 |
|
Laxatives |
|
Phase 3 |
|
|
|
28 |
|
Somatomedin B |
|
Phase 3 |
|
|
|
29 |
|
Hemagglutinins |
|
Phase 3 |
|
|
|
30 |
|
Taxane |
|
Phase 3 |
|
|
108169 |
31 |
|
polysaccharide-K |
|
Phase 3 |
|
|
|
32 |
|
PENTA |
|
Phase 3 |
|
|
|
33 |
|
Aluminum hydroxide |
Approved, Investigational |
Phase 2 |
|
21645-51-2 |
|
Synonyms:
Al(OH)3
Aldrox
Algeldrate
Algeldrate atlas brand
Algeldrate axcan brand
Algeldrate chefaro brand
Algeldrate roques brand
Algeldrate stiefel brand
Algeldrate whitehall brand
Algeldrate wyeth brand
Alhydrogel
ALterna gel
Alugel
Alumina, hydrated
Aluminio hidróxido
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
Aluminiumhydroxid
Aluminum hydroxide
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Amphojel
|
Atlas brand OF algeldrate
Axcan brand OF algeldrate
Basalgel
Brasivil
chefaro Brand OF algeldrate
Dialume
Dried aluminium hydroxide
Dried aluminum hydroxide gel
Dried aluminum hydroxide gel fine granules
Hydrated alumina
Hydroxide, aluminum
Nephrox
Pepsamer
Rhône poulenc rorer brand OF algeldrate
Rhône-poulenc rorer brand OF algeldrate
Rocgel
Roques brand OF algeldrate
Sanofi winthrop brand OF algeldrate
SmithKline beecham brand OF algeldrate
Stiefel brand OF algeldrate
Whitehall brand OF algeldrate
Wyeth brand OF algeldrate
|
|
34 |
|
Sargramostim |
Approved, Investigational |
Phase 2 |
|
123774-72-1 |
|
Synonyms:
B1 61.012
B1-61012
LEUKINE
RECOMBINANT GM-CSF
Recombinant human granulocyte-macrophage colony stimulating factor
|
rGM-CSF
RHU GM-CSF
RHU-GM-CSF
SARGRAMOSTIM
|
|
35 |
|
Temozolomide |
Approved, Investigational |
Phase 2 |
|
85622-93-1 |
5394 |
Synonyms:
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
BRN 5547136
CCRG 81045
CCRG-81045
CCRIS 8996
m & b 39831
m And b 39831
m And b39831
m And b-39831
M&B 39831
M&B-39831
M-39831
MB 39831
Methazolastone
NSC 362856
NSC-362856
|
SCH 52365
SCH-52365
Temodal
Temodar
TEMOMEDAC
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
Temozolomide
Témozolomide
Temozolomide hexyl ester
Temozolomidum
Temozolomidum [Latin]
TMZ
TMZ Bioshuttle
TMZA-he
TMZ-Bioshuttle
|
|
36 |
|
Molgramostim |
Investigational |
Phase 2 |
|
99283-10-0 |
|
Synonyms:
|
MOLGRAMOSTIM (GENETICAL RECOMBINATION)
SCH-39300
|
|
37 |
|
Antibodies, Monoclonal |
|
Phase 1 |
|
|
|
38 |
|
Immunoglobulins, Intravenous |
|
Phase 1 |
|
|
|
39 |
|
BCG vaccine |
Approved, Investigational |
|
|
|
|
Synonyms:
BACILLUS CALMETTE GUERIN VACCINE
BACILLUS CALMETTE GUÉRIN VACCINE
Bacillus Calmette–Guérin (BCG) vaccine
|
Bacillus calmette-guerin live antigen, unspecified substrain
BCG
BCG vaccine
|
|
40 |
|
D-Phenylalanine |
Approved, Experimental, Investigational, Nutraceutical |
|
|
63-91-2, 673-06-3 |
6140 71567 |
Synonyms:
(-)-beta-Phenylalanine
(6S)-Tetrahydrofolate
(6S)-Tetrahydrofolic acid
(6S)-THFA
(L)-Phenylalanine
(S)-(-)-Phenylalanine
(S)-2-Amino-3-phenylpropanoate
(S)-2-Amino-3-phenylpropanoic acid
(S)-2-Amino-3-phenylpropionate
(S)-2-AMINO-3-PHENYLPROPIONIC ACID
(S)-a-Amino-b-phenylpropionate
(S)-a-Amino-b-phenylpropionic acid
(S)-alpha-Aminobenzenepropanoate
(S)-alpha-Amino-benzenepropanoate
(S)-alpha-Aminobenzenepropanoic acid
(S)-alpha-Amino-benzenepropanoic acid
(S)-alpha-Amino-beta-phenylpropionate
(S)-ALPHA-AMINO-BETA-PHENYLPROPIONIC ACID
(S)-alpha-Aminohydrocinnamate
(S)-alpha-Aminohydrocinnamic acid
(S)-Phenylalanine
(S)-Α-amino-β-phenylpropionate
(S)-Α-amino-β-phenylpropionic acid
3-PHENYL-L-ALANINE
5,6,7,8-Tetrahydrofolate
5,6,7,8-Tetrahydrofolic acid
a-Amino-b-phenylpropionate
a-Amino-b-phenylpropionic acid
alpha-Amino-beta-phenylpropionate
alpha-Amino-beta-phenylpropionic acid
alpha-Aminohydrocinnamate
|
alpha-Aminohydrocinnamic acid
beta-Phenylalanine
beta-Phenyl-alpha-alanine
BETA-PHENYL-L-ALANINE
b-Phenyl-L-alanine
D-(+)-phenylalanine
DL-Phenylalanine
Endorphenyl
F
FEMA NO. 3585
Fenilalanina
L-2-Amino-3-phenylpropionate
L-2-Amino-3-phenylpropionic acid
L-Isomer phenylalanine
L-PHE
L-Phenylalanine
NSC-79477
PHE
Phenylalamine
Phenylalanin
Phenylalanine
Phenyl-alanine
Phenylalanine, L isomer
Phenylalanine, L-isomer
Phenylalaninum
Tetrahydrofolate
THF
Α-amino-β-phenylpropionate
Α-amino-β-phenylpropionic acid
Î’-PHENYL-L-ALANINE
|
|
41 |
|
Anti-Bacterial Agents |
|
|
|
|
|
42 |
|
Anti-Infective Agents |
|
|
|
|
|
43 |
|
Serine |
Investigational, Nutraceutical |
|
|
56-45-1 |
5951 |
Synonyms:
(-)-Serine
(2S)-2-Amino-3-hydroxypropanoate
(2S)-2-Amino-3-hydroxypropanoic acid
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-b,b-carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-BETA,BETA-carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-β,β-carotene-3,3'-diol
(S)-(-)-Serine
(S)-2-Amino-3-hydroxypropanoate
(S)-2-Amino-3-hydroxy-propanoate
(S)-2-Amino-3-hydroxypropanoic acid
(S)-2-Amino-3-hydroxy-propanoic acid
(S)-a-Amino-b-hydroxypropionate
(S)-a-Amino-b-hydroxypropionic acid
(S)-alpha-Amino-beta-hydroxypropionate
(S)-alpha-Amino-beta-hydroxypropionic acid
(S)-b-Amino-3-hydroxypropionate
(S)-b-Amino-3-hydroxypropionic acid
(S)-beta-Amino-3-hydroxypropionate
(S)-beta-Amino-3-hydroxypropionic acid
(S)-Serine
(S)-Α-amino-β-hydroxypropionate
(S)-Α-amino-β-hydroxypropionic acid
2-Amino-3-hydroxypropanoate
2-Amino-3-hydroxypropanoic acid
3-Hydroxy-L-alanine
|
alpha-Amino-beta-hydroxypropionic acid
beta-Hydroxyalanine
beta-Hydroxy-L-alanine
b-Hydroxyalanine
b-Hydroxy-L-alanine
Bo-xan
e 161b
L Serine
L-(-)-Serine
L-2-Amino-3-hydroxypropionate
L-2-Amino-3-hydroxypropionic acid
L-3-Hydroxy-2-aminopropionate
L-3-Hydroxy-2-aminopropionic acid
L-3-Hydroxy-alanine
L-Ser
L-Serin
L-Serine
S
Ser
Serina
SERINE
Serinum
Xanthophyll
Î’-hydroxyalanine
Î’-hydroxy-L-alanine
|
|
Interventional clinical trials:
(show top 50)
(show all 292)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis Vaccine (DTaP) and Measles, Moms and Rubella Vaccine (MMR) |
Unknown status |
NCT04638985 |
Phase 4 |
|
2 |
A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis (DTaP) Vaccine and Live Attenuated Hepatitis A Vaccine (HepA) |
Unknown status |
NCT04636827 |
Phase 4 |
|
3 |
An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age |
Unknown status |
NCT00870350 |
Phase 4 |
|
4 |
A Prospective, Open-label, Interventional Phase IV Study to Assess the Safety of EupentaTM Inj. {Fully Liquid Pentavalent Vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [Recombinant-deoxyribonucleic Acid])-Haemophilus Influenzae Type b Conjugate Vaccine} |
Unknown status |
NCT04056728 |
Phase 4 |
|
5 |
Safety and Immunogenicity of Adult Formulation Tetanus and Diphtheria Toxoids Adsorbed Combined With Acellular Pertussis (Tdap) Vaccine Following Blood and Morrow Transplantation in Adults |
Unknown status |
NCT00336115 |
Phase 4 |
|
6 |
The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis |
Unknown status |
NCT01301703 |
Phase 4 |
|
7 |
Open Label Multicentric Randomized Phase IV Post Marketing Safety, Immunogenicity and Lot-to-Lot Consistency Analysis of Shan 5 [DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine] in Indian Infants |
Unknown status |
NCT00877357 |
Phase 4 |
|
8 |
Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine) |
Completed |
NCT00777257 |
Phase 4 |
|
9 |
Immunogenicity and Safety of Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) for Adult Use Vaccine Compared With U.S. Manufactured Tetanus and Diphtheria Toxoids Adsorbed for Adult Use Vaccine In Persons 60 Years of Age and Older and Immunogenicity and Safety of Canadian Td Vaccine in Persons 11 Through 59 Years of Age |
Completed |
NCT00601835 |
Phase 4 |
|
10 |
Evaluation of GSK Biologicals' dTpa Booster Vaccine in Adults, Given 10 Years After Previous dTpa Boosting. |
Completed |
NCT00548171 |
Phase 4 |
|
11 |
An Open, Multicentric, Post-marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants. |
Completed |
NCT00325156 |
Phase 4 |
|
12 |
Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexaâ„¢) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrixâ„¢ During Pregnancy or Immediately Post-delivery |
Completed |
NCT02422264 |
Phase 4 |
Prevnar13 |
13 |
Antibody Persistence in Children Previously Vaccinated With Three Doses of Infanrix Hexaâ„¢ or Infanrix-IPV/Hibâ„¢ |
Completed |
NCT01358825 |
Phase 4 |
|
14 |
Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexaâ„¢ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrixâ„¢ During Pregnancy or Immediately Post-delivery |
Completed |
NCT02853929 |
Phase 4 |
|
15 |
A Single Blind, Multicentric, Comparative, Vaccine Interchangeability Trial of Shan 5 (Liquid) and Easy Five (Liquid) [Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib Pentavalent Combination Vaccines] in Indian Infants. |
Completed |
NCT00674908 |
Phase 4 |
|
16 |
Immunogenicity and Safety of Two-Dose Series of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284; Menactra®) in Japanese Healthy Adult Subjects |
Completed |
NCT02591290 |
Phase 4 |
|
17 |
Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) in Persons ≥65 Years of Age |
Completed |
NCT00457249 |
Phase 4 |
|
18 |
A Prospective, Randomized, Open-label Clinical Trial to Assess the Safety and Immunogenicity of Simultaneous vs Sequential Administration of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and Inactivated Influenza Vaccine in Pregnant Women - Pilot |
Completed |
NCT02783170 |
Phase 4 |
|
19 |
Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACELâ„¢ (HCP20/20/5/3DT-mIPV//PRP-T) |
Completed |
NCT00802867 |
Phase 4 |
|
20 |
Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants |
Completed |
NCT01926015 |
Phase 4 |
|
21 |
Immune Responses in Adults to Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose |
Completed |
NCT00712959 |
Phase 4 |
|
22 |
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. |
Completed |
NCT01659996 |
Phase 4 |
|
23 |
Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine After Concomitant Vaccination in ≥50-year-old Adults |
Completed |
NCT03552445 |
Phase 4 |
|
24 |
Safety Among Adolescents and Adults of Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) 4 to 5 Years After a Previous Dose |
Completed |
NCT00347958 |
Phase 4 |
|
25 |
Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACELâ„¢ and BOOSTRIX® |
Completed |
NCT00319553 |
Phase 4 |
|
26 |
Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination |
Completed |
NCT00304265 |
Phase 4 |
|
27 |
Regulatory Post-Marketing Surveillance (PMS) Study for ADACELâ„¢ (Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined Vaccine for Adult) |
Completed |
NCT01137435 |
Phase 4 |
|
28 |
Meningococcal (Groups A, C, Y, W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) Post-Marketing Safety Study in Healthy Children (2-11 Years), Adolescents (12-17 Years) and Adults (18-55 Years) in the Philippines |
Completed |
NCT01270503 |
Phase 4 |
|
29 |
Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIMâ„¢(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis) |
Completed |
NCT01437423 |
Phase 4 |
|
30 |
A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine |
Completed |
NCT01424644 |
Phase 4 |
|
31 |
Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants |
Completed |
NCT02907216 |
Phase 4 |
|
32 |
Postmarketing Surveillance Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in the Republic of Korea |
Completed |
NCT02864927 |
Phase 4 |
|
33 |
Adacel® (TdaP-Tetanus, Diphtheria, Acellular Pertussis) Booster Vaccination of Acellular Pertussis Vaccine-primed Individuals for Cell Mediated Immunity Assay Development |
Completed |
NCT04543669 |
Phase 4 |
|
34 |
Prospective, Randomized, Controlled, Observer-Blind Trial to Measure the Efficacy, Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccine and the Safety and Immunogenicity of Quadrivalent Meningococcal Polysaccharide Diphtheria Conjugate Vaccine in Pregnant Malian Women and Their Infants up to 6 Months of Age |
Completed |
NCT01430689 |
Phase 4 |
|
35 |
A Phase IV Study to Evaluate the Primary and Booster Immune Responses of UK Infants Receiving a Licensed 6-in-1 DTaP/IPV/Hib/HBV Vaccine (Infanrix-HexaTM) With a 13-valent Pneumococcal Conjugate Vaccine and Incorporating a Randomisation Study of a Single Dose of 3 Different Meningococcal Group C Conjugate Vaccines at 3 Months of Age |
Completed |
NCT01896596 |
Phase 4 |
|
36 |
Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting. |
Completed |
NCT00635128 |
Phase 4 |
|
37 |
Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age. |
Completed |
NCT00514059 |
Phase 4 |
Boostrix polio |
38 |
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa Vaccine in Healthy Infants |
Completed |
NCT00753649 |
Phase 4 |
|
39 |
An Open Label Multicentric Study to Evaluate the Immunogenicity and Safety of Indigenously Developed DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine (Shan 5) in Indian Infants. |
Completed |
NCT00617812 |
Phase 4 |
|
40 |
Evaluation of GSK Biologicals' dTpa Booster Vaccine in Young Adults 10 Years After Previous dTpa Boosting. |
Completed |
NCT00610168 |
Phase 4 |
|
41 |
Immunogenicity and Reactogenicity Study of a New Formulation of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children |
Completed |
NCT00611559 |
Phase 4 |
|
42 |
Non-specific Effects of Vaccines - In Search of the Immunological Background |
Completed |
NCT00168545 |
Phase 4 |
|
43 |
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents |
Completed |
NCT01629589 |
Phase 4 |
|
44 |
Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIMâ„¢) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIMâ„¢ in the Study E2I34 |
Completed |
NCT01031303 |
Phase 4 |
|
45 |
Evaluation of GSK Biologicals' Boostrixâ„¢ in Healthy Adults, 10 Years After Previous Booster Vaccination |
Completed |
NCT01147900 |
Phase 4 |
|
46 |
Assessment of the Immunogenicity and Safety of PENTAXIMâ„¢ in Philippines |
Completed |
NCT00254917 |
Phase 4 |
|
47 |
Safety & Immunogenicity of a Booster Dose of dTPa Vaccine (Boostrix®) Co-admnd. With Aventis Pasteur's Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Vaccine (Menactraâ„¢) vs Admn. of Either Vaccine Alone in Healthy Adolescents |
Completed |
NCT00282295 |
Phase 4 |
|
48 |
Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand |
Completed |
NCT00255021 |
Phase 4 |
|
49 |
Immunogenicity and Safety Study of GSK Biologicals' dTpa Vaccine, Boostrixâ„¢ (263855) in Pregnant Women |
Completed |
NCT02377349 |
Phase 4 |
Saline placebo |
50 |
Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose |
Completed |
NCT01439165 |
Phase 4 |
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Diphtheria Antitoxin
|
Equine diphtheria antitoxin
|
|